| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment | 289 | ACCESS Newswire | - Tome Foundational Treatment, powered by Bioneedle, is now available for purchase at www.tomeskincare.com -- Once-weekly Foundational Treatment is designed to renew the appearance of skin and improve... ► Artikel lesen | |
| DERMATA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.08. | Dermata opens preorders for Tome skincare product | 2 | Investing.com | ||
| 21.08. | Dermata Therapeutics: Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch | 336 | ACCESS Newswire | - Preorders can be made by visiting www.tomeskincare.com -- Dermata is ready to begin shipping orders on the expected launch date of August 25, 2026 -- Tome Foundational Treatment is a once-weekly topical... ► Artikel lesen | |
| 17.08. | NSE - Dermata Therapeutics, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
| 17.08. | Dermata Therapeutics announces $3.4M private placement | 4 | Seeking Alpha | ||
| 17.08. | Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules | 347 | ACCESS Newswire | $3.4 million upfront with up to approximately $6.7 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESS Newswire / August 17, 2026 / Dermata Therapeutics... ► Artikel lesen | |
| 17.08. | Dermata Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.08. | Dermata Therapeutics Stock Surges 27% Pre-Market: Why is it Moving? | 4 | Benzinga.com | ||
| 12.08. | Dermata Therapeutics: First Commercial Launch Arrives With $4.4 Million Cash And Runway Into Q4 | 1 | pulse2.com | ||
| 11.08. | Dermata Therapeutics GAAP EPS of -$0.74 misses by $0.19 | 1 | Seeking Alpha | ||
| 11.08. | Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026 | 893 | ACCESS Newswire | - Dermata announced the launch date of its first commercial product, Tome Foundational Treatment, expected on August 25, 2026 -- Dermata recently attended Be+Well Beauty and Wellness Show in Las Vegas... ► Artikel lesen | |
| 11.08. | Dermata Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 05.08. | Dermata Therapeutics Announces Commercial Launch Date for Tome Foundational Treatment | 376 | ACCESS Newswire | - A new chapter in skincare has arrived -- This will be Dermata's first commercial product launch, planned for August 25, 2026 -- Join the waitlist at tomeskincare.com - SAN DIEGO, CA / ACCESS Newswire... ► Artikel lesen | |
| 05.08. | Dermata Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 04.06. | Dermata Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 4 | SEC Filings | ||
| 27.05. | Dermata Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.05. | Dermata Therapeutics GAAP EPS of -$0.48 beats by $0.05 | 3 | Seeking Alpha | ||
| 13.05. | Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026 | 382 | ACCESS Newswire | - Dermata announced their Tome Skincare brand for direct-to-consumer ("DTC") skincare products -- Dermata plans to launch its first DTC product, the Tome Foundational Treatment, a once-weekly mask to... ► Artikel lesen | |
| 13.05. | Dermata Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 13.05. | Dermata Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,30 | +0,11 % | BioNTech Aktie: Im Rausch der Moderna-Euphorie - Doch wie lange hält die Party an? | © Foto: von fernando zhiminaicela auf Pixabay (Symbolbild)Fast 30 Prozent in einer einzigen Woche. Das ist lange her, dass sowas bei BioNTech vorkam. Zuletzt wohl zu Pandemie-Zeiten ging es mal so zur... ► Artikel lesen | |
| EVOTEC | 3,348 | -1,06 % | Rheinmetall-Aktie verkaufen? Evotec mit KI-Fantasie? Lahontan Gold hebt Ressourcenschätzung um 22 %! | Soll man die Rheinmetall-Aktie verkaufen? Dazu rät jedenfalls mwb Research. Die Analysten sehen Rheinmetall operativ weiterhin als klaren Gewinner des europäischen Rüstungsbooms. Doch die Erwartungen... ► Artikel lesen | |
| BB BIOTECH | 59,40 | -0,17 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| QIAGEN | 37,590 | -0,42 % | DAX Verlierer: Qiagen Aktie | Kursentwicklung und Chartanalyse | ||
| MODERNA | 119,06 | -0,03 % | Moderna Aktie: Was für ein Wahnsinn bei Moderna! Kippt aber jetzt die Stimmung?! | © Foto: Finanznachrichten (Symbolbild wurde mit KI erstellt)Erst ein Kurssprung wie ihn kaum eine Aktie je erlebt hat, dann der schnelle Absturz, aber kommt jetzt wieder eine Erholung? Moderna sorgt... ► Artikel lesen | |
| VALNEVA | 2,798 | +0,76 % | Katalysator voraus: Valneva (ISIN: FR0004056851) setzt auf Q3-Shigella-Daten | ||
| NOVAVAX | 7,950 | -0,62 % | Novavax announces regulatory approvals for updated COVID shot | ||
| STRYKER | 285,30 | -0,07 % | Do Options Traders Know Something About Stryker Stock We Don't? | ||
| BIOGEN | 187,62 | -0,51 % | Veeva Systems: Veeva Vault CRM Selected by Biogen | Unified commercial platform to help speed the delivery of medicines to patientsPLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has... ► Artikel lesen | |
| BIOFRONTERA | 2,500 | +2,46 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,360 | -0,85 % | CRISPR Therapeutics legt positive Einjahresdaten für Gentherapie CTX310 vor | ||
| REGENERON PHARMACEUTICALS | 682,40 | -0,41 % | Veeva Systems: Veeva Vault CRM Selected by Regeneron | Leading biopharma company selects agentic CRM for life sciences to generate Commercial EvidencePLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced... ► Artikel lesen | |
| BIOXXMED | 1,230 | 0,00 % | PTA-News: bioXXmed AG: Einladung zur Hauptversammlung | DJ PTA-News: bioXXmed AG: Einladung zur Hauptversammlung
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Einladung zur Hauptversammlung
Heidelberg (pta000/20.07.2026/15:45... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,730 | 0,00 % | Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy | ||
| ARCUTIS BIOTHERAPEUTICS | 23,780 | 0,00 % | Here's Why You Should Add ARQT Stock to Your Portfolio Now |